Anti‐VEGFA therapy in wet AMD is considered to be safe for patients, even although some side‐effects have been reported.12, 57 Moreover, Papudesu et al showed that AREDS2 participants with wet AMD in one eye at baseline had a statistically significant increased risk for mortality compared with patients having no or only a few drusen.58 Moreover, a visual acuity less than 20/40 was associated with a reduced survival. Here, VEGFA is linked to wet macular degeneration.